1-Piperidine Propionic Acid 通过抑制蛋白酶受体2保护人免受败血栓冲击
Roberto Luisetto1, Marco Scarpa1, Gianmarco Villano1
1Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
International journal of molecular sciences
|November 9, 2024
概括
小分子1-Piperidine Propionic Acid (1-PPA) 在实验模型中有效降低了败血症症状和死亡率. 这种向性药物阻断了蛋白酶激活受体2 (PAR2),减轻了炎症反应,改善了器官功能.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 病理生理学 病理生理学
背景情况:
- 败血症是一种危及生命的疾病,其特点是宿主对感染的反应失调,导致高发病率和死亡率.
- 目前的败血症治疗方法在调节免疫反应和维持血管功能方面面临挑战.
- 蛋白酶激活受体2 (PAR2) 被确定为败血症炎症反应的关键调节器.
研究的目的:
- 为了研究1-Piperidine Propionic Acid (1-PPA) 作为针对败血症的向剂的治疗潜力.
- 评估1-PPA在阻断PAR2和减轻实验性内毒性病的炎症途径中的疗效.
- 评估1-PPA对败血症相关死亡率,症状,心脏功能和器官病理学的影响.
主要方法:
- 利用THP-1细胞系来评估1-PPA对脂聚糖 (LPS) 诱导的细胞因子表达的影响.
- 将1-PPA注射给LPS注射的小鼠,以评估其对死亡率,败血症症状和心脏功能的影响.
- 在肺和肝组织中分析了细胞因子水平 (IL-6,IL-1β,IL-10) 和血管活性分子 (kininogen-1).
- 对各种器官进行了体病理学分析,以评估败血症引起的损伤.
主要成果:
- 1-PPA在THP-1细胞中表现出LPS诱导的细胞因子表达的剂量依赖抑制.
- 在注射LPS的小鼠中,1-PPA治疗显著降低了死亡率和败血症相关症状.
- 在接受1-PPA.治疗的小鼠中,心脏功能参数得到改善.
- 在接受1-PPA治疗的小鼠的肺和肝组织中观察到IL-6,IL-1β,IL-10和kininogen-1的显着减少.
- 在1-PPA注射后,表明败血症的组织病理发现显著减少.
结论:
- 1-Piperidine Propionic Acid (1-PPA) 在治疗败血症方面显示出显著的治疗潜力.
- 使用1-PPA阻止蛋白酶激活受体2 (PAR2) 有效地减轻了败血症引起的炎症和器官损伤.
- 1-PPA代表了一种有前途的分子向剂,用于治疗败血症,改善存活率和器官功能.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
358
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
358
Gene Regulation in Microbial Communities: Quorum Sensing
3
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
3
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
355
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
355
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
542
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
542
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
471
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
471


